Do Statins Have Antidepressant Effects?
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
Statins are used widely in primary and secondary prevention of cardiovascular disease; a treatment effect that has long been thought to be due to their cholesterol-lowering properties. However, statins also have a wide range of anti-inflammatory effects independent of their lipid-lowering mechanisms. In depression, low-grade inflammation is a replicated finding, and several studies have shown antidepressant properties of diverse anti-inflammatory drugs. Large observational studies have suggested reduced risks of depression amongst those taking statins, an effect that is thought to be explained by the anti-inflammatory properties of this class of drugs. Also, preliminary randomized controlled trials (RCTs) have indicated that statins may have adjunctive antidepressant effects when used as add-on treatment to selective serotonin reuptake inhibitors (SSRIs). However, the RCTs were small and limited by low generalizability, and some early observational studies have pointed towards potential neuropsychiatric adverse effects of statin treatment. Nevertheless, based on the good tolerability and general safety of the statins, researchers are currently investigating the potential antidepressant properties of these agents. The present review aims to give an overview on the potential antidepressant effects of statins based on their anti-inflammatory properties, covering topics such as safety versus treatment effects, potential mechanisms of action and the possibility of targeted treatme…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examples include statins, aspirin and angiotensin antagonists.788, 789, 790, 791, 792, 793”
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 2×
“Also, a minor increased risk of diabetes mellitus has been suggested [47, 56], which may be most pronounced among patients with other risk factors for diabetes [56].”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 15×
“Indeed, in some trials, CRP seemed to be a better biomarker for CVD prevention than low-density lipoprotein cholesterol (LDLC) [46, 50, 51].”
InfluentialOverweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Depression is a major cause of disability worldwide, but despite state-of-the-art treatment including augmentation strategies, remission rates following antidepressant medications are low [1, 2].”
InfluentialSCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationWium-Andersen, M. K., Wium-Andersen, I. K., Prescott, E. I. B., Overvad, K., Jørgensen, M. B., & Osler, M. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.130 · Cited by 87
The concept of violent suicide, its underlying trait and neurobiology: A critical perspective
Ludwig, B., & Dwivedi, Y. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.12.001 · Cited by 62
Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?
Moreira, E. G., Boll, K. M., Correia, D. G., Soares, J. F., Rigobello, C., & Maes, M. H. J. (2018) · Current Neuropharmacology · doi:10.2174/1570159x17666181227164947 · Cited by 59
Shared genetic liability between major depressive disorder and osteoarthritis
Zhang, F., Rao, S., & Baranova, A. V. (2022) · Bone and Joint Research · doi:10.1302/2046-3758.111.bjr-2021-0277.r1 · Cited by 58
Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
Giorgi, R. D., Pesci, N. R., Quinton, A. M. G., Crescenzo, F. D., Cowen, P. J., & Harmer, C. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.702617 · Cited by 56
De Giorgi, R., De Crescenzo, F., Rizzo Pesci, N., Martens, M., Howard, W., Cowen, P. J., & Harmer, C. J. (2021) · PLOS ONE · doi:10.1371/journal.pone.0249409 · Cited by 52
Statin treatment and the risk of depression
Köhler‐Forsberg, O., Gasse, C., Petersen, L. V., Nierenberg, A. A., Mors, O. N., & Østergaard, S. D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.110 · Cited by 46
Self-citationGe, Z., Hu, Y., Kan, W., Li, L., Xu, J., Zhang, Y., Zheng, N., Wang, G., & Du, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625087 · Cited by 42
Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study
Fabbri, C., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., Rujescu, D., Mendlewicz, J., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110050 · Cited by 39
Drug repurposing may generate novel approaches to treating depression
Ebada, M. E. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12815 · Cited by 38
Update on Statin Treatment in Patients with Neuropsychiatric Disorders
Avan, R., Sahebnasagh, A., Hashemi, J., Monajati, M., Faramarzi, F., Henney, N. C., Montecucco, F., Jamialahmadi, T., & Sahebkar, A. (2021) · Life · doi:10.3390/life11121365 · Cited by 35
Fabbri, C., & Serretti, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.484 · Cited by 19
Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Rahman, R. R., Hamirani, M. M., Hodsoll, J. P., Carvalho, A. F., Husain, N., & Young, A. H. (2019) · BJPsych Open · doi:10.1192/bjo.2018.84 · Cited by 18
Xiao, X., Deng, H., Li, P., Sun, J., & Tian, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1203444 · Cited by 17
Gutlapalli, S. D., Farhat, H., Irfan, H., Muthiah, K., Pallipamu, N., Taheri, S., Thiagaraj, S. S., Shukla, T. S., Giva, S., & Penumetcha, S. S. (2022) · Cureus · doi:10.7759/cureus.32323 · Cited by 16
Vieira, G. C., Cavalli, J., Gonçalves, E. C. D., Gonçalves, T. R., Laurindo, L. R., Cola, M., & Dutra, R. C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00584 · Cited by 16
Gutlapalli, S. D., Chaudhuri, D., Khan, K. I., Shouli, R. A., Allakky, A., Ferguson, A. A., Khan, A. I., Abuzainah, B., & Mohammed, L. (2022) · Cureus · doi:10.7759/cureus.32331 · Cited by 10
Köhler‐Forsberg, O., Petersen, L. V., Berk, M., Gasse, C., & Østergaard, S. D. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.004 · Cited by 8
Self-citationFeatures of mental disorders and their correction in patients with cardiac pathology
Zhidyaevskij, A. G., Mendelevich, В. D., Galyautdinov, G. S., Ibragimova, K. R., & Бакиевна, З. Э. (2020) · Kazan medical journal · doi:10.17816/kmj2020-212 · Cited by 3
Ali, E., & Abouelella, A. (2022) · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences · doi:10.21608/rpbs.2022.177123.1188 · Cited by 2
So, H., Chau, C. K., & Zhao, K. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/170241 · Cited by 2
Muniandy, N. D., Kasim, N. A. M., & Aziz, L. H. A. (2023) · The Malaysian Journal of Nursing · doi:10.31674/mjn.2023.v15i02.003 · Cited by 1
Tailoring antidepressant therapy based on genetic profiles
Shammari, Y. H. A., Shammari, H. A. A., Barak, T. M. B., Alharbi, B. S., Alshammari, S. T., Alnais, S. A., Aljohani, S. A., Alorf, A. A., Alnawmasi, M. A., Alshammari, M. A., et al. (2018) · International Journal of Health Sciences · doi:10.53730/ijhs.v2ns1.14915 · Cited by 1
Buoli, M., Esposito, C. M., Ceresa, A., Paolo, M. D., Legnani, F., Pan, A., Ferrari, L., Bollati, V., & Monti, P. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00743-4 · Cited by 1
Central nervous system effects of statins: benefit or risk?
Rutkowska, M. (2018) · Farmacja Polska · doi:10.32383/farmpol/118769
Jaworska, E., & Skowron, A. (2018) · Farmacja Polska · doi:10.32383/farmpol/118761
Lipid-lowering therapy of cardiovascular diseases (literature review)
Biletskyi, S. V., Kazantseva, T., Petrynych, O., & Petrynych, V. V. (2021) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxv.4.100.2021.19
Su, D., Song, Y., Liao, Z., Liu, Y., Liao, L., Zhang, Z., Zhu, G., Yang, M., luo, X., & Ai, Z. (2022) · Authorea · doi:10.22541/au.165157026.67760952/v1
Neuroscience of Violence and Suicidal Behavior
Ludwig, B., & Dwivedi, Y. (2026) · Wiley eBooks · doi:10.1002/9781118832202.ch16
Breit, S. (2026) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20260006
Cheng, Y., Huang, H., Chen, X., Sun, X., Xie, H., Wang, M. X., Xie, J., Luo, Y., Chen, Z., Fan, H., et al. (2026) · Archives of Medical Science · doi:10.5114/aoms/218062
Rodríguez-Romero, M. D., Carabí‐Gassol, P., Cabana‐Domínguez, J., Llonga, N., Zubizarreta‐Arruti, U., Graell, M., Macias‐Chimborazo, V., Ramos‐Quiroga, J. A., Arteaga-Henríquez, G., Ribasés, M., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112901
Debele, G. R., Davoodian, N., Lotfaliany, M., Wolfe, R. S., Berk, M. P., Tonkin, A. M., Williams, L. J., Lacaze, P., Yu, C., Clayton‐Chubb, D., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122695
Self-citation
Metadata
- Authors
- Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D.
- Affiliations
- Aarhus University (DK)
- Deakin University (AU)
- Venue
- CNS Drugs
- Published
- 2017-03-16
- Volume
- 31
- Issue
- 5
- Pages
- 335-343
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2595471035
- Cited by
- 31
- References
- 101
- Citations by year
- 2026: 3 · 2025: 2 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 4
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Lundbeckfonden (R155-2014-1724, R165–2013–15320)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- statins, antidepressant effects, depression, anti-inflammatory activity, low-grade inflammation, selective serotonin reuptake inhibitors, neuropsychiatric adverse effects, precision medicine, mechanism of action
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Antidepressive Agents, Depressive Disorder, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.